{"nctId":"NCT02025751","briefTitle":"Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis","startDateStruct":{"date":"2014-04","type":"ACTUAL"},"conditions":["Diabetic Gastroparesis"],"count":53,"armGroups":[{"label":"Metoclopramide Nasal Spray","type":"EXPERIMENTAL","interventionNames":["Drug: Metoclopramide Nasal Spray"]},{"label":"Placebo Nasal Spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Nasal Spray"]}],"interventions":[{"name":"Metoclopramide Nasal Spray","otherNames":[]},{"name":"Placebo Nasal Spray","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male subjects between the ages of 18 and 75 years\n* Willingness and ability to give written informed consent\n* The ability to read, understand and speak English\n* Prior diagnosis of Type 1 or Type 2 diabetes\n* Diagnosis of diabetic gastroparesis with confirmation of delayed gastric emptying\n* A mean daily gastroparesis symptom score of ≥1.4 and ≤3.5 prior to randomization\n* Willingness to discontinue current treatment for diabetic gastroparesis and to avoid all proscribed (excluded) medications, as specified by the protocol, for the duration of the study\n\nExclusion Criteria:\n\n* Gastric bypass, gastric banding, gastric pacemaker, post surgical causes of gastroparesis and disorders known to be associated with abnormal gastrointestinal motility\n* A history of allergic or adverse responses, including, but not limited to, acute dystonic reactions and tardive dyskinesia, to metoclopramide or any comparable or similar product\n* A history of, or physical findings suggestive of, tardive dyskinesia\n* A history of epilepsy or currently using and unwilling or unable stop other drugs known to be associated with extrapyramidal reactions at screening\n* Malignancy (with the exception of treated squamous cell or basal cell carcinoma of the skin) currently present, initially diagnosed or recurring within five (5) years of screening\n* Renal dysfunction calculated as creatinine clearance (CrCl) \\<40 mL/min at screening\n* Hemoglobin A1c \\>11.5% at screening","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure","description":"Change from the Baseline Period to Week 4 of the Treatment Period in the mean daily Gastroparesis Symptom Assessment (GSA) total score for subjects receiving Metoclopramide Nasal Spray 10 mg versus subjects receiving placebo. The GSA minimum value is 0 (no symptoms) and the maximum value is 4 (very severe symptoms). A higher score is a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.751","spread":"0.4673"},{"groupId":"OG001","value":"-0.657","spread":"0.9042"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Throat irritation","Liver palpable","Platelet count decreased","Malaise","Pyrexia"]}}}